Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telbivudine + peginterferon alpha-2a
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Telbivudine + peginterferon alpha-2a is an experimental, unapproved combination therapy of the nucleoside analogue **telbivudine** and the pegylated interferon **peginterferon alpha-2a** for the treatment of *chronic hepatitis B*. Telbivudine inhibits hepatitis B virus (HBV) DNA polymerase by acting as a chain terminator, thereby inhibiting viral DNA synthesis and replication[4][6]. Peginterferon alpha-2a is a recombinant modified interferon that binds human type I interferon receptors, activating the JAK/STAT pathway and stimulating the innate antiviral immune response[2][8]. The combination showed rapid and profound reductions in HBV DNA but was associated with a significantly increased risk of peripheral neuropathy, leading to early termination of clinical studies and strong recommendations against its clinical use[1][8][9].
- Brand names
- Sebivo + Pegasys
- Other names
- telbivudine + pegylated interferon alpha-2atelbivudine + pegylated interferon
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on telbivudine + peginterferon alpha-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telbivudine + peginterferon alpha-2a.